Core Viewpoint - The innovative pharmaceutical sector is experiencing a resurgence, driven by improved fundamentals, supportive policies, and increased market interest, particularly in the A-share and Hong Kong markets [1][3][12]. Group 1: Market Performance - The pharmaceutical sector has shown strong performance this year, with a notable rebound starting from April 9, despite recent pullbacks [1]. - The innovative drug segment in A-shares and Hong Kong stocks has continued to strengthen, indicating a recovery after four years of adjustment [1][3]. - The total amount of business development (BD) transactions for innovative drugs is projected to rise significantly, from $8.4 billion in 2020 to $51.9 billion in 2024 [4]. Group 2: Policy and Industry Trends - The policy environment has shifted from cost control to encouraging innovation, providing strong support for the development of innovative drugs [3]. - The number and quality of innovative drug products in China have significantly improved, leading to increased interest from foreign pharmaceutical companies [3][5]. - The penetration rate of innovative drugs in China is expected to rise, with current levels at around 20%, compared to 70%-80% in the U.S. [5]. Group 3: Investment Opportunities - Fund managers are optimistic about the future of innovative drugs, emphasizing the importance of technology and growth attributes in the sector [6]. - Investment strategies include focusing on high-quality companies, innovative drug leaders, and traditional pharmaceutical companies transitioning to innovative drugs [7][8][9]. - Investors can consider actively managed pharmaceutical funds or industry-themed ETFs to gain exposure to the innovative drug market [10][12]. Group 4: Fund Performance - Several funds managed by 工银瑞信 have demonstrated strong performance, ranking highly in their respective categories over various time frames [13][15]. - The 工银港股通创新药ETF has seen significant inflows, reflecting market preference for innovative drug companies [11].

金融界2025年6月23日消息，工银医疗保健股票(000831) 最新净值2.5760元，增长1.18%。该基金近1个 月收益率-0.46%，同类排名514|1026；近6个月收益率11.85%，同类排名173|993；今年来收益率 13.03%，同类排名137|997。 公开资料显示，工银医疗保健股票基金成立于2014年11月18日，截至2025年3月31日，工银医疗保健股 票规模27.24亿元，基金经理为赵蓓、丁洋。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今,担任工银瑞 信前沿医疗股票型基金基金经理。2018年7月30日至2019年12月23日起担任工银瑞信医药健康行业股票 型证券投资基金基金经理。2020年05月20日至2022年6月14日担任工银瑞信科技创新6个月定期开放混合 型证券投资基金基金经理。2025年4月9日起担任工银瑞信新经济灵活配置混 ...

医药生物行业资金流出榜 （原标题：14.41亿元主力资金今日抢筹医药生物板块） 沪指6月23日上涨0.65%，申万所属行业中，今日上涨的有28个，涨幅居前的行业为计算机、国防军工，涨幅分别为2.25%、1.97%。医药生物行业 今日上涨0.89%。跌幅居前的行业为食品饮料、家用电器、钢铁，跌幅分别为0.80%、0.43%、0.11%。 医药生物行业今日上涨0.89%，全天主力资金净流入14.41亿元，该行业所属的个股共475只，今日上涨的有400只，涨停的有6只；下跌的有65只， 跌停的有1只。以资金流向数据进行统计，该行业资金净流入的个股有247只，其中，净流入资金超亿元的有5只，净流入资金居首的是永安药业， 今日净流入资金2.35亿元，紧随其后的是塞力医疗、华海药业，净流入资金分别为1.65亿元、1.25亿元。医药生物行业资金净流出个股中，资金净 流出超3000万元的有9只，净流出资金居前的有众生药业、创新医疗、新诺威，净流出资金分别为1.42亿元、6423.29万元、5901.06万元。（数据 宝） 医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量 ...

Core Viewpoint - ICBC Medical Care Stock (000831) has experienced a decline of 1.27% on June 19, with a latest net value of 2.56 yuan, marking a cumulative drop of 7.84% over five consecutive trading days [1] Group 1: Fund Performance - The fund was established in November 2014, with a total scale of 2.724 billion yuan and a cumulative return of 156.40% since inception [1] - As of the end of 2024, institutional investors hold 0.41 million shares, accounting for 3.55% of total shares, while individual investors hold 11.19 million shares, making up 96.45% of total shares [1] Group 2: Fund Management - Current fund manager Zhao Bei has a master's degree and has been with ICBC Credit Suisse since 2010, serving as the fund manager since November 18, 2014 [2] - The current fund manager Ding Yang holds a doctoral degree and joined ICBC Credit Suisse in December 2017, taking over as fund manager on May 5, 2023 [2] Group 3: Portfolio Holdings - As of March 31, 2025, the top ten holdings of ICBC Medical Care Stock account for a total of 39.79%, with major positions including: - Heng Rui Medicine (8.90%) - WuXi AppTec (5.12%) - Aier Eye Hospital (4.94%) - BeiGene (3.77%) - Zai Lab (3.52%) - New Horizon Health (3.27%) - Mindray Medical (2.80%) - Yuwell Medical (2.76%) - United Imaging Healthcare (2.47%) - Innovent Biologics (2.24%) [3]

Group 1 - The core viewpoint of the news is that the ICBC Frontier Medical Stock C (010685) has experienced a decline of 1.24% on June 19, with a cumulative drop of 8.33% over the last five trading days, and its latest net value is 2.94 yuan [1] - The fund was established in November 2020, with a total fund size of 1.38 billion yuan, and has recorded a cumulative return of -10.43% since inception [1] - As of the end of 2024, institutional investors hold 0.20 million shares, accounting for 3.55% of the total shares, while individual investors hold 5.51 million shares, making up 96.45% of the total [1] Group 2 - The current fund manager, Zhao Bei, has a master's degree and has been with ICBC Credit Suisse since 2010, currently serving as the deputy director of the research department and head of the healthcare research team [2] - Zhao has managed several funds, including the ICBC Healthcare Industry Stock Fund since November 2014 and the ICBC Frontier Medical Stock Fund since February 2016 [2] - As of March 31, 2025, the top ten holdings of ICBC Frontier Medical Stock C account for a total of 59.05%, with major holdings including Heng Rui Medicine (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [2]

证券代码：300765 证券简称：新诺威 公告编号：2025-055 石药创新制药股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 1 序 号 委托方 受托方 产品名称 产品 类型 资金来 源 认购金额 （万元） 起息日 到期日 收益 (万元) 1 石药创新 制药股份 有限公司 中国民生 银行股份 有限公司 石家庄分 行 聚赢汇率-挂钩 欧元对美元汇 率结构性存款 （SDGA25203 1Z） 保本 浮动 收益 闲置募 集资金 40,000.00 2025 年 5 月 8 日 2025 年 6 月 8 日 61.83 一、现金管理产品到期赎回情况 三、关联关系说明 公司与上述银行不存在关联关系。 四、审批程序 《关于使用部分闲置募集资金及自有资金进行现金管理的议案》已经公司第 六届董事会第二十二次会议、第六届监事会第十七次会议及 2024 年年度股东大 会审议通过，公司独立董事、监事会、保荐机构均发表了明确同意的意见。公司 本次进行现金管理的额度和期限均在审批范围内，无需另行提交董事会、股东大 会审议。 五、投资风险和风险控制措施 （一）投资风险 1、主要受货币政策、财政政策、产业政策等宏观政策及 ...

Group 1 - Vanke A announced the sale of 22 million A-share treasury stocks for a total of 146 million yuan, representing 0.18% of the company's total share capital, aimed at supplementing liquidity without impacting current profits [1] - Tencent Music plans to acquire 100% of Himalaya for a total consideration of $1.26 billion, which includes cash and shares, to expand its audio content ecosystem [1] - Dongfang Electric Heat signed a strategic cooperation agreement with Xiaomi's subsidiary to develop robotic electronic skin, focusing on flexible fabric pressure sensing applications [3] Group 2 - Chengdu Huamei launched a 4-channel, 12-bit, 16G high-precision RF direct sampling ADC chip, marking a significant breakthrough in high-speed data conversion technology [4] - Jinshi Technology clarified that it has not engaged in any business related to stablecoins, despite recent market interest, and noted a significant stock price increase of 76.51% over six trading days [5] - Xiantan Co. reported a 14.22% year-on-year increase in chicken product sales revenue for May, amounting to 469 million yuan [7]

证券代码：300765 证券简称：新诺威 公告编号：2025-054 石药创新制药股份有限公司 关于控股子公司 SYS6040 抗体偶联药物 获得美国药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、概述 石药创新制药股份有限公司（以下简称"公司"）的控股子公司石药集团巨石 生物制药有限公司（以下简称"巨石生物"）于近日收到美国食品药品监督管理 局（以下简称"FDA"）通知，由巨石生物申报的注射用 SYS6040 药品临床试验 申请已获得美国 FDA 批准，可以在美国开展临床试验。现将相关情况公告如下： 二、药物的基本信息 药物名称：SYS6040 剂 型：注射剂 此前，SYS6040 已经于 2025 年 3 月获得中华人民共和国国家药品监督管理 局批准，可以在中国开展临床试验。具体内容详见公司刊登于巨潮资讯网（htt p://www.cninfo.com.cn）的《关于控股子公司 SYS6040 抗体药物偶联物获得药 物临床试验批准通知书的公告》（公告编号：2025-028）。 四、风险提示 申请事项：临床试验 IND 编号 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive returns in various time frames [1] - The latest net value of the fund is 2.7270 yuan, with a growth of 1.79% [1] - The fund's performance over the past month has yielded a return of 8.91%, ranking 96 out of 1025 in its category [1] - Over the last six months, the fund has achieved a return of 13.01%, ranking 146 out of 989 [1] - Year-to-date, the fund has returned 19.66%, ranking 96 out of 999 [1] Group 2 - The top ten holdings of the fund account for a total of 39.79%, with significant positions in companies such as Heng Rui Pharmaceutical (8.90%) and WuXi AppTec (5.12%) [1] - The fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan [1] - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector [2]

创新药概念股反复活跃，新诺威（300765）尾盘20cm涨停，常山药业（300255）涨超16%创出历史新 高，迈威生物、赛伦生物涨超10%，海创药业、神州细胞跟涨。 ...